

# AGENDA

**Translational Advances in Cancer Prevention Agent Development**  
*Sponsored by the Division of Cancer Prevention, National Cancer Institute  
and the Office of Disease Prevention*

*National Institutes of Health*

*Bethesda, MD 20892*

**DATE: August 27-29, 2020**

**Day 1 Morning Session (8:00 to 12:00)**

- 7:00-8:00 AM      **Registration** (Please allow sufficient time to go through security)
- 8:00-8:30 AM      **Welcome Remarks**
- Deborah Winn, Ph.D., Acting Director, Division of Cancer Prevention, NCI
- Mark Miller, Ph.D. Program Director, Division of Cancer Prevention, NCI
- 8:30-9:30 AM      **Translational Research Plenary Speaker**
- Raymond DuBois, M.D., Ph.D., Medical University of South Carolina  
*Inflammation and inflammatory mediators as targets for cancer prevention/interception*

**Session I\***

**Advances in Small Molecule Agent Development**

*Co-Chairs: Margie Clapper, Ph.D. and Thomas Kensler, Ph.D.*

- 9:30-10:00 AM      Speaker 1: Margie Clapper, Ph.D. Fox Chase Cancer Center
- Estrogen metabolism: A target for intervention in non-small cell lung cancer*
- 10:00-10:30 AM      Speaker 2: Thomas Kensler, Ph.D., Fred Hutchinson Cancer Research Center
- Bringing broccoli sprouts (Sulforaphane) to clinical trials: dose matters*
- 10:30-10:50 AM      Break**
- 10:50-11:20 AM      Speaker 3: Zelton (Dave) Sharp, Ph.D., University of Texas at San Antonio
- Cancer and aging prevention by mTOR inhibition*
- 11:20-11:50 AM      Speaker 4: Karen Liby, Ph.D., Michigan State University
- Targeting the immune system for the prevention of Kras-driven cancers*
- 11:50-1:15 PM      Lunch**

**Day 1 Afternoon Session (1:15 to 4:30)**

**Session II**

**Advances in Immunomodulatory Agent Development**

*Co-chairs: Jill Siegfried, Ph.D. and Robert H. Shoemaker, Ph.D.*

- 1:15-1:45 PM      Speaker 1: Jill Siegfried, Ph.D., University of Minnesota  
*A STAT3 decoy for lung cancer prevention*
- 1:45-2:15 PM      Speaker 2: Robert Glynn, Sc.D., Harvard Medical School  
*Mediation analysis to elucidate the role of inflammation reduction in cancer prevention: exploratory findings from the CANTOS trial*
- 2:15-2:45 PM      Speaker 3: Haval Shirwan, Ph.D., University of Missouri, Columbia  
*CD137 immune checkpoint pathway as an effective target for cancer immunoprevention*
- 2:45-3:00 PM      Break
- 3:00-3:30 PM      Speaker 4: Shadmehr Demehri, M.D., Ph.D., Massachusetts General Hospital  
*Epithelium-derived alarmins role in breast cancer immunoprevention*
- 3:30-3:50 PM      **NCI PREVENT Preclinical Drug Development Program**  
Mark Miller, Ph.D., Division of Cancer Prevention, NCI
- Q&A Session until 4:30 PM

**4:30-6:00 PM      Poster Session**

**Day 2 Morning Session (9:00 to 12:00)**

**Session III**

**Alternative Dosing and Combination Strategies to Reduce Toxicity**

*Co-Chairs: Ming You, M.D., Ph.D. and Altaf Mohammed, Ph.D.*

- 9:00-9:30 AM      Speaker 1: Ming You, M.D., Ph.D., Wisconsin Medical Center  
*Chemoprevention with aerosolized let-7 micro-RNA in mouse models of lung cancer*
- 9:30-10:00 AM      Speaker 2: Susan Mallery, D.D.S., Ph.D., Ohio State University  
*Location, location, location: oral cancer chemoprevention by local delivery*
- 10:00-10:30 AM      Speaker 3: C.V. Rao, Ph.D., University of Oklahoma  
*Safer chemopreventive approaches to colonic adenoma prevention*
- 10:30-10:45 AM      Break**
- 10:45-11:15 AM      Speaker 4: D. Lynn Kirkpatrick, Ph.D., PHusis Therapeutics  
*Preventing Skin cancer in high risk individuals with Actinic Keratosis using targeted AKT/PDK1 inhibitor, PHT-427*
- 11:15-11:45 AM      Speaker 5: Roderick Dashwood, Ph.D., Texas A&M Health Science Center  
*Optimizing dosing regimens of Erlotinib and Sulindac in a preclinical model of FAP*
- 11:45-1:00 PM      Lunch**

**Day 2 Afternoon Session (1:00 to 4:00)**

**Session IV**

**Emerging Vaccines for Cancer Prevention**

*Co-Chairs: Steven Lipkin, M.D., Ph.D. and Shizuko Sei, M.D.*

- |                     |   |
|---------------------|---|
| 1:00-1:30 PM        | Speaker 1: Steven Lipkin, M.D., Ph.D. Weill Cornell University<br><i>Immunoprevention for Lynch Syndrome</i>  |
| 1:30-2:00 PM        | Speaker 2: Mary (Nora) Disis, M.D., University of Washington<br><i>Vaccines targeting cancer initiation associated proteins</i>                           |
| 2:00-2:30 PM        | Speaker 3: Richard Roden, Ph.D., Johns Hopkins University<br><i>Development of vaccines for broad protection against and elimination of HPV infection</i> |
| 2:30-2:50 PM        | <b>Break</b>  |
| 2:50-3:20 PM        | Speaker 4: Robert Schoen, M.D., M.P.H., University of Pittsburgh<br><i>MUC1 vaccine for prevention of colorectal adenoma</i>                              |
| 3:20-3:50 PM        | Speaker 5: Bryon Johnson, Ph.D., Wisconsin Medical Center<br><i>Development of a Kras preventive vaccine</i>  |
| <b>4:00-6:00 PM</b> | <b>Poster Session</b>   |

**Day 3 Morning Session (8:00 to 12:00)**

8:00-9:00 AM

**Clinical Research Plenary Speaker**

Powel Brown, M.D., Ph.D., MD Anderson Cancer Center

*Novel cancer prevention strategies in the molecular era*

**Session V**

**Cancer Prevention Clinical Trials**

Co-Chairs: Peter Allen and Eva Szabo

9:00-9:15 AM

**Overview of the Cancer Prevention Clinical Trials Network (CP-CTNet)**

Eva Szabo, M.D., Division of Cancer Prevention, NCI

Q&A to 9:30 AM

9:30-10:00 AM

Speaker 1: Peter Allen, M.D., Duke University

*Intraductal Papillary Mucinous neoplasms of the pancreas: An opportunity to prevent pancreatic cancer?*

10:00-10:30 AM

Speaker 2, Eduardo Vilar-Sanchez, M.D., Ph.D., MD Anderson Cancer Center

*Cancer immune-interception for Lynch Syndrome*

**10:30-10:50 AM**

**Break**

10:50-11:20 AM

Speaker 3: Seema Khan, M.D., Northwestern University

*Local transdermal drug delivery to the breast for cancer prevention*

11:20-11:50 AM

Speaker 4: Andrew Chan, M.D., M.P.H., Massachusetts General Hospital

*Novel strategies for aspirin prevention of cancer*

12:00 PM

**Adjourn**